Open AccessResults of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation
Unc LibrariesG Spencer-Green +292020
The content you want is available to Zendy users.
Already have an account? Sign inHaving issues? Contact support